## Aging, Anti-Aging, and Biopreservation

For most of human history, aging was something you endured, not something you treated. That framing is changing. A well-funded and rapidly advancing field now treats aging itself as a condition — potentially a treatable one — and the implications touch everything from medicine to economics to the basic structure of human life.

### What Has Changed Since 2018

The longevity field has exploded since the book was published. Several developments are converging:

**Senolytics** — drugs that selectively destroy senescent cells (cells that have stopped dividing but remain metabolically active, secreting inflammatory signals that contribute to aging) — have moved from animal studies to human clinical trials. The idea is elegant: remove the cells that are actively making you older.

**Cellular reprogramming** using Yamanaka factors — the same transcription factors that can turn adult cells back into stem cells — is being investigated as a way to reverse aging at the cellular level without fully reverting cells to a stem-like state. Altos Labs, founded in 2022 with $3 billion in funding, is pursuing this approach. Calico, Alphabet's longevity subsidiary, has been working on aging biology since 2013.

**Epigenetic clocks** — molecular markers that estimate biological age based on chemical modifications to DNA — have given researchers a way to measure aging with precision, enabling faster evaluation of interventions. If you can measure aging accurately, you can test whether something slows or reverses it.

**Biopreservation** represents a related but distinct frontier. Technologies for preserving organs — vitrification (ice-free cryopreservation), machine perfusion (keeping organs alive outside the body), and nanowarming (uniformly rewarming preserved tissue using nanoparticles) — could transform transplantation medicine. The current system depends on a narrow time window between organ recovery and transplant. Extending that window from hours to days, weeks, or potentially longer would fundamentally change the organ shortage crisis. It would mean more organs reaching more patients, fewer organs wasted, and the possibility of banking organs the way we bank blood.

### Why It Matters

The equity question is unavoidable. The book's [Elysium](/md-files/movies_elysium.md) chapter imagined a world where transformative medical technology was available to the privileged and denied to everyone else. If aging interventions work, the question of who can afford them will be one of the most consequential equity issues of the century. A world where the wealthy live decades longer than the poor is not speculative — it is the logical endpoint of current trends in health access. See [If we can extend human life dramatically, should we? And who gets to?](/md-files/ceq_extending_life.md)

The [Hype vs. Reality](/md-files/ntf_hype_vs_reality.md) framework is essential here. The longevity field generates extraordinary claims. Some are backed by rigorous science; others are driven by billionaire enthusiasm and venture capital impatience. Counting assumptions — the book's Occam's Razor discipline — is a critical tool for distinguishing therapies that might work in humans from results that look promising in mice.

Biopreservation raises its own set of the book's questions. It sits at the intersection of [Bioprinting and Organ Regeneration](/md-files/est_bioprinting.md) and [Technological Convergence](/md-files/ntf_technological_convergence.md) — the advances depend on nanotechnology, cryobiology, and engineering working together. And the [Too Valuable to Fail](/md-files/rei_too_valuable_to_fail.md) framework applies: these technologies are potentially so beneficial that the pressure to deploy them will be intense, even before all the risks are fully understood.

### Explore Further

- [Bioprinting and Organ Regeneration](/md-files/est_bioprinting.md) — the book's treatment of medical technology access
- [Power, Privilege, and Access](/md-files/rei_power_privilege_access.md) — who benefits from breakthrough medicine
- [Hype vs. Reality](/md-files/ntf_hype_vs_reality.md) — separating real progress from longevity hype
- [Technological Convergence](/md-files/ntf_technological_convergence.md) — how multiple fields enable biopreservation
- [CRISPR Babies and Embryo Selection](/md-files/p18_crispr_babies_embryo_selection.md) — related questions about engineering the human body
- [If we can extend human life dramatically, should we?](/md-files/ceq_extending_life.md) — the complex emerging question